OCTA Changes in Choroidal Neovascularization in High Myopia

NCT ID: NCT06357559

Last Updated: 2024-04-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-04-30

Study Completion Date

2024-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV..

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To Analyze the Ability of Optical Coherence Tomography Angiography ( OCT-A ) to detect the presence of myopic Choroidal Neovascularization and to describe the structural features of Myopic CNV.. regarding the size , shape , core , margin , Appearance , and activity of CNV..

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopic Choroidal Neovascularisation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OCTA

Optical Coherence Tomography Angiography

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All Patients with High Myopia ( \> -6 D or Axial Length \> 26.5 mm ) with Fundoscopic Changes Consistent with CNVM , with Clear Media are Subjected to OCTA

Exclusion Criteria

* Patients with Treated CNVs , or with other Causes of CNVs including :

Neovascular AMD , Idiopathic CNV , Traumatic , Inflammatory , Neoplastic , Degenerative ..
Minimum Eligible Age

10 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sohag University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Hamdy Abdelrahman

Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ahmed Hamdy

Role: CONTACT

01287307536

References

Explore related publications, articles, or registry entries linked to this study.

Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res. 2018 Mar;63:92-106. doi: 10.1016/j.preteyeres.2017.10.005. Epub 2017 Oct 28.

Reference Type BACKGROUND
PMID: 29111299 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OCTA in Myopic CNV

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.